Emergent BioSolutions makes vaccines and other products intended to protect civilian and military populations from emerging infectious diseases and chemical, biological or nuclear attacks. The company generates most of its revenue from product sales of its smallpox vaccine (ACAM2000), its anthrax vaccines (BioThrax and AV7909), and its Narcan nasal spray (a treatment for opioid overdoses). It also generates revenue from contract development and manufacturing services, as well as from contracts and grants. The USG is the company's primary customer, and provides it with significant product development funding. EBS shares are a component of the S&P 600 Index. The company has approximately 2,200 employees.
MRK, DRI, SPH
Jasper HellwegAssociate Analyst: Growth Pharmaceutical, Medical Technology & Financial Technology